Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new NIHR funded trial will compare whether either fixing the broken bone or replacing the hip joint gives a better result for people over 60

© Twinsterphoto/Shutterstock

Every year around 70,000 people in the UK, and 1.3 million globally, break their hip. Facing increasingly ageing populations these numbers are projected to rise to more than 100,000 by 2020 in the UK. The problem is estimated to cause the loss of 1.75 million disability adjusted life years per year globally, and represents 1.4% of the total healthcare burden in established market economies.

A new study, FRUITI, will look at treatments for one specific type of hip fracture. Minimally displaced intracapsular fractures, those that occur at the head of the femur, and may have loss of blood supply to the bone, represent approximately ten to fifteen per cent of all hip fractures. Currently, there are two treatments available. Surgeons either repair the fracture with screws or remove and replace the broken piece of bone, but it's not known which is better for patients.

Xavier Griffin, Associate Professor of Trauma Surgery at NDORMS, University of Oxford, explained: "Treatment of this type of fracture by fixing the broken bone is a quick procedure which has the advantage of preserving the patient's own hip joint. However, healing can be unsuccessful with patients requiring revision surgery in perhaps 30% of cases. Hip replacement surgery eliminates the risk of fixation failure as the femoral neck is replaced. But it is a more major operation with very significant complications of its own including a greater risk of infection, dislocation and periprosthetic fracture."

Developed by a team of patient representatives, clinical experts in trauma orthopaedics, study management specialists, experienced statisticians and health economists, the study will compare the two treatments for people 60 years and over. They will recruit 878 people to the study from 40 hospitals across the UK, and review patients health, walking ability and other daily activities, as well as any complications and specific costs at the outset, and at 6 weeks, 4 months and 1 year after the injury.

Fruiti is funded by the National Institute for Health Research (NIHR).

Similar stories

NDORMS researchers awarded for Dupuytren research

Awards Hand Kennedy Main

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

Arthritis Kennedy Main

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.

NDORMS academics named NIHR Senior Investigators

Main

Congratulations to Professor Jonathan Rees who has been announced as a National Institute of Health Research (NIHR Senior Investigator).